cyrilzakka/clinical-trials huggingface dataset:
Effects of a Contextual Decision-making Materials on Junior Nurses in Traumatic Learning Performance

Trauma leading to severe bleeding is one of the reasons for the high mortality rate in trauma patients, resulting in multiple and complex injuries from various accidental mechanisms. However, patients with abdominal-pelvic trauma accidents rank among the top three common accidents in the emergency department. There is a potential for both trauma and severe internal bleeding, making the care of such patients even more challenging. Currently, trauma nursing education focuses on emergency medical care, and teaching on the care of abdominal-pelvic trauma occupies only a small part of the entire nursing curriculum.

In addition to insufficient knowledge teaching in emergency trauma medical care, learning relies heavily on the arrangement of clinical internships, and obtaining practical experience in the care of abdominal-pelvic trauma is often difficult. In the current era of thriving digital learning, allowing learning to be more diverse and unrestricted by time and location, it is essential to integrate appropriate guiding strategies alongside digital technology to make learning more efficient and promote meaningful learning.

Therefore, this study introduces decision trees into an interactive scenario-based learning environment for the care of severe bleeding due to abdominal-pelvic trauma. The decision tree is coupled with a decision-making strategy, utilizing the relationships between leaf nodes to guide learners in clarifying their misconceptions, ultimately leading them to make appropriate decisions to reach the final nodes and solve problems.

To understand the effectiveness of this study, a real experimental research design is adopted to investigate the impact of introducing decision tree-based interactive teaching materials on the care of severe bleeding in abdominal-pelvic trauma situations on the professional knowledge, self-efficacy, clinical reasoning assessment ability, and technology acceptance of surgical nursing students over a two-year period. It is hoped that this interactive teaching material for the care of severe bleeding in abdominal-pelvic trauma scenarios will enhance learners' professional knowledge, self-efficacy, clinical reasoning assessment, and technology acceptanc.


Eligibility Criteria:
Inclusion Criteria:

* Holding a nursing license, employed, and having job registration in the same institution.
* Those who are willing to participate in this study, are informed, and have provided consent by signing the informed consent form

Exclusion Criteria:

* Those who have completed a service period of more than two years
* Those who refuse to participate in this study.
* Non-Surgical Department ward nurses
Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507

The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.


Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 19 years or over
2. Patients with LDL-C levels ≤ 250 mg/dL, TG \< 500 mg/dL
3. Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study

Exclusion Criteria:

1. Severe congestive hear failure
2. Current active liver disease
3. The use of prohibiterd concomitant therapies
4. Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding, active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is not controlled by medication, etc.

6.Women who were of childbearing potential without contraception, pregnant, or breastfeeding
The Role of Maintaining External Carotid Artery Flow in Graft Interposition After Carotid Endarterectomy

Analyzing results of carotid graft interposition with and without flow preservation through external carotid artery after endarterectomy.

Surgical and endovascular treatment have been shown as effective treatment modalities in symptomatic and asymptomatic patients at high risk of stroke on medical therapy with significant carotid artery stenosis. Eversion carotid endarterectomy (eCEA) has proven effective as a surgical treatment modality. In highly selected instances carotid bypass may be indicated as a bailout procedure or primarily as a preoperatively planned maneuver. Usually, the decision for substitution of carotid bifurcation with a synthetic graft is made due to an extensive, severe atherosclerotic process on the distal part of the extracranial internal carotid artery, the presence of uncontrollable atherosclerotic plaque after endarterectomy, and in cases when an exceptionally thin artery wall remains after endarterectomy.

Several techniques have been described for substituting carotid bifurcation with a synthetic graft. The most common technique involves complete resection and excision of the carotid bifurcation and reconstruction with graft interposition between the undiseased segment of the common carotid artery (CCA) proximally and the internal carotid artery (ICA) distally by creating proximal and distal end-to-end anastomoses. This technique requires ligation and exclusion of the external carotid (ECA) and the superior thyroid artery from circulation. The less common techniques that preserve flow through the external carotid artery are performed as a primary option for treatment without previous endarterectomy and are seldom applied. Currently, there are no recommendations regarding the administration of carotid bypass, nor comparisons of these techniques.

In this study, the investigators are comparing a technique with graft interposition between endarterectomized CCA (creation of side-to-end anastomosis) and the distal segment of the ICA (end-to-end anastomosis) after failure of eCEA to provide technical success with the described common interposition by end-to-end anastomoses proximally and distally. Therefore, the role of flow preservation through the ECA could be defined.

Eligibility Criteria:
Inclusion Criteria:

* symptomatic carotid stenosis (\> 50%)
* unilateral asymptomatic carotid stenosis (\> 60%)
* bilateral asymptomatic carotid stenosis (\> 60%)

Exclusion Criteria:

* carotid restenosis
* "major surgery" in previous 6 months
* previous brain trauma or surgery
* malignant disease
* epilepsy
* carotid artery aneurysm
Maternal Immunization: Giving Immunity For Tomorrow

Study objectives are to compare

* influenza antibody levels in infant sera and maternal colostrum or breast milk at delivery, 2, and 6 months women who receive influenza immunization in early pregnancy, late pregnancy, or no influenza immunization during pregnancy and their infants

Study hypotheses are that infants born to pregnant women who receive influenza immunization in late pregnancy will have

* higher levels and a longer serum influenza antibody duration in sera (hemagglutination inhibition (HAI) titers) and colostrum/breast milk (influenza-specific IgA and IgG by enzyme-linked immunosorbent assay (ELISA) than infants of women immunized in early pregnancy or not immunized


Eligibility Criteria:
Inclusion Criteria:

Pregnant women 18-45 years of age from 8-36 weeks gestation in good health as determined by medical history and recent physical exam who

* receive prenatal care at the UUHS Obstetrics and Gynecology Clinics and their infants
* plan to seek care for their infant at the UUHS affiliated Pediatric Clinics (UUHS or SMC Pediatric Clinics)
* plan for their infant to receive influenza immunization at 6 and 7 months of age

Exclusion Criteria:

* maternal history of either a congenital or acquired immunodeficiency including infection (e.g. HIV), chronic steroid use, or malignancy
* serious underlying neurological, cardiac, renal, or pulmonary disease in either the mother or infant
* multiple gestation
* antenatal or postnatal detection at delivery of any major birth defect in the infant
* delivery of the infant before 37 weeks
Efficacy of Inspiratory Muscle Training on Elite Swimmers

This study is a randomized controlled trial on the efficacy of inspiratory muscle training on swimming performance, airway dysfunction and perceived breathlessness in elite swimmers.

Only a few studies have assessed the impact of Inspiratory Muscle Training (IMT) on swim performance with unclear and inconsistent results. This study aims to evaluate the effect of a 12-week IMT program in swimming performance, airway dysfunction and perceived breathlessness among elite swimmers. Participants will be recruited from the elite competitive Futebol Clube do Porto swimming team. After consent, individuals will be randomly allocated into the IMT or Sham-IMT group. A pressure threshold device will be used to perform the inspiratory training. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice a day, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP). Sham-IMT group will follow a similar protocol, except for the inspiratory effort that will be made against 15% of MIP. Measures of lung function, swimming performance, airway dysfunction, inspiratory muscle strength and perceived breathlessness will be assessed at the beginning and then in 4 weeks intervals until the end of study period. All outcome measures will be assessed by an investigator who will be not involved in the intervention process. Data will be expressed as mean ± standard deviation (SD) and respective 95% confidence interval. The significance level will be 5% (p˂0.05).

Eligibility Criteria:
Inclusion Criteria:

* Healthy elite swimmers engaged in competitive training for a minimum period of three years;
* Individuals with no disability;
* Individuals aged between 14 and 40 years.

Exclusion Criteria:

* Individuals presenting co-morbidities or physical impairment that affects regular training;
* Smokers;
* Athletes already in a regular respiratory muscle training program
* Individuals with a predicted forced expiratory volume in the first second (FEV1) below 60%.
The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment

The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients .
2. Confirmed by Histopathology or Cytology of Lung Cancer
3. Patients should be voluntary to the trial and provide with signed informed consent
4. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories
2. Pregnant or lactating women
3. Patients with Albumin-binding taxol contraindications
4. Patients of doctors considered unsuitable for the trial
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab induction with maintenance treatment.

The hypothesis is that at least a subset of CFS patients have an activated immune system involving B-lymphocytes, and that prolonged B-cell depletion may alleviate symptoms.


Eligibility Criteria:
Inclusion Criteria:

* patients with CFS
* age 18-66 years
* informed consent

Exclusion Criteria:

* patients with fatigue, not fulfilling criteria for CFS
* pregnancy or lactation
* previous malignant disease except basal cell carcinoma of skin and cervical carcinoma in situ
* previous major immunological disease, except autoimmune diseases such as diabetes mellitus or thyroiditis
* previous long-term use of immunosuppressive drugs, except steroids e.g. in obstructive lunge disease
* endogenous depression
* lack of ability to comply by the protocol
* multi-allergy with risk of serious drug reaction
* reduced renal function (creatinin \> 1.5 x UNL)
* reduced liver function (bilirubin or transaminases \> 1.5 x UNL)
* HIV positivity
* evidence of clinically significant infection
Role of Uttarbasti in the Management of Mutra Marga Sankoch (Urethral Stricture)

Uttarbasti is per urethral administration of medicated oil which has been recommended by Sushrut for urinary track disorders.

As far as conventional surgery is concerned urethral stricture still remains a challenge due to post procedural high recurrences and complications

Uttarbasti being almost non invasive, with minimum recurrences and most economical, easy to practice OPD procedure, can be the treatment of choice in the management of urethral stricture.


Eligibility Criteria:
Inclusion Criteria:

* K/C/O Urethral Stricture of either sex and from all age groups.

Exclusion Criteria:

* With acute UTI.
* DM.
* Neoplasms of lower urinary tract
* BEP.
* With impacted calculus in urethra and bladder neck.
Review of Kidney Biopsies of Dent Disease Patients

This study is being done to obtain pathology reports from all patients in the Dent disease registry who have had a kidney biopsy. The investigator will collect the biopsy slides and reports in an attempt to determine if they have any common findings.

If the patient agrees to be in the study, the patient will be asked to participate in the following:

* Sign a consent form indicating the patient's willingness to participate.
* Provide a signed medical release form allowing the investigator to request your official kidney biopsy reports, and also allowing the investigator to request the original slides for review. At the end of the study, all slides will be returned to the referring facility.
* The investigator will also review your medical record

Eligibility Criteria:
Inclusion Criteria:

* All patients in the Dent Disease Registry with a previous renal biopsy.

Exclusion Criteria:

* None.
Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

The aim of this study is to characterize the genetic and cellular immunological parameters of metastatic digestive cancer patients having short and long responses to chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

For all patients:

* signed written informed consent

For cohort A:

* patient with metastatic colorectal cancer with first-line therapy by chemotherapy +/- surgery and with a disease-free survival \> or = at 20 months
* Ct-scan realized in the previous 4 weeks and showing no progression according to the Recist criteria v1.1

For cohort B:

* patient treated for metastatic colorectal cancer and chemotherapy responder (obtention of an objective response according to the Recist criteria V1.1 in first-line therapy), with a disease-free survival \< 10 months (disease progression must be confirmed by CT scan evaluation according to Recist v1.1 criteria)

For cohort C:

* patients with no metastatic rectum cancer in complete remission after chemotherapy and/or radiotherapy

For cohort D:

* patients with metastatic or locally advanced cancer in complete remission after treatment, non eligible in the other cohorts

Exclusion Criteria:

For all patients:

* patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study
* patient with a neurodegenerative disease
* patient under guardianship, curator or under the protection of justice
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer

Objective:

Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.

Patients:

Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.

Interventions:

Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay.

Hypothesis:

Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.

Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).

Eligibility Criteria:
Inclusion Criteria:

* Female patients attending mammography, average age of the fourth and fifth decades.

Exclusion Criteria:

* Patients with hormonal therapy.
An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis

PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This phase 2 efficacy and safety study will assess topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Men or women, age 18 or older.
* Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous areas).
* Fitzpatrick skin type I-VI.
* Written informed consent by the subject or legal guardian.

Exclusion Criteria:

* Women of childbearing potential who are pregnant, attempting to conceive, not using effective contraception, or who are nursing an infant.
* Subjects who have received PUVA or systemic antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28 days of study initiation (two weeks for methotrexate).
* Subjects who have received UVB light therapy within 14 days of study initiation.
* Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin or Vitamin D analogs) to the study plaque areas within 14 days of study initiation.
* Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of study initiation.
* Subjects who have received any approved or investigational biologic drug therapy for psoriasis within 90 days or 5 half-lives of study initiation.
* Subjects who have participated in a clinical research study within 28 days of study initiation.
* Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
* Subjects with clinical conditions that, in the opinion of the Investigator may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke


Eligibility Criteria:
Inclusion criteria:

Age \>= 18 years at screening(visit 1A) but \<= 80 years Signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial Diagnosis of ischemic stroke with a measureable neurological deficit on National Institute of Health Stroke Scale (NIHSS) Thrombolytic therapy can be initiated within 3 to 4.5 hours of stroke onset Further inclusion criteria apply

Exclusion criteria:

Evidence of intracranial haemorrhage (ICH) on the (Computer Tomography) CT/(Magnetic Resonance Imaging)MRI-scan or symptoms suggestive of subarachnoid haemorrhage, even if the CT/MRI-scan is normal Acute bleeding diathesis Severe stroke as assessed clinically( e.g. National Institute of Health Stroke Scale\>25) and/ or imaging demonstrates multi-lobar infarction (hypodensity \>1/3 cerebral hemisphere) Severe uncontrolled arterial hypertension, e.g. systolic blood pressure\>185 mmHg or diastolic blood pressure\>110mmHg, or aggressive management (intravenous medication) necessary to reduce blood pressure to these limits Blood glucose \<50mg/ dL or \>400 mg/dL Any history of prior stroke in previous 3 months, or any history of prior stroke with concomitant diabetes Seizure at stroke onset Further exclusion criteria apply
Investigating Brown Adipose Tissue Activation in Humans

The purpose of this study is to determine what can activate brown adipose tissue (BAT).

We will investigate different stimuli (i.e. hormones) to determine which can stimulate BAT.

Eligibility Criteria:
Inclusion Criteria:

* aged \>18 years

Exclusion Criteria:

* medical conditions
* recreational drug use
* participation in other trials within the preceding 2 months
* blood donation within 3 months of study participation
Airway Anatomy of the SimBaby

The aim of the present study is to compare radiographic upper airway measurements of the SimBabyTM pediatric patient high-fidelity simulator with actual human airway anatomy to assess the grade of realism of the simulator.


Eligibility Criteria:
Inclusion Criteria:

* MRI or CT head or neck including upper airway
* age: 1-12 months

Exclusion Criteria:

* no pathology of airway, face, neck
* no airway device in place
* head not in neutral position
* neck collar
Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency

Eligible patients were randomized into two groups: Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.

The primary and secondary outcomes will be collected.

Eligible patients with chronic intestinal failure/insufficiency were randomly assigned to one of two groups, Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.

The primary and secondary outcomes will be collected.

Eligibility Criteria:
Inclusion Criteria:

1. Informed consent was obtained from patients or their legal representatives for participation in this study
2. Patients 18 years of age or older, under 70 years of age, chronic intestinal failure/insufficiency
3. Serum 25(OH)D level \< 30.0 ng/ml
4. Vital signs are stable

Exclusion Criteria:

1. Those who did not meet the inclusion criteria, or who were deemed unfit by their physician to participate in this study
2. Primary hypothyroidism or parathyroidism
3. Patients suffering from allergic diseases, are allergic, have a history of drug sensitivity similar to the structure of the study drug
4. Patients with primary diabetes
5. Patients with mental illness, inability to cooperate or consciousness disorders
6. Patients with contraindications of experimental drugs
7. Patients with a suspected or confirmed history of substance abuse
8. Immune deficiency, use of immunosuppressants and hormones
9. Pregnant and lactating women
10. Have taken any vitamin D supplements in the last 6 months
11. Have taken any medication in the last 6 months that affects vitamin D metabolism (e.g., phenytoin, phenobarbital, rifampicin)
12. Patients who participated in a drug trial (including the drug in the trial) within 3 months before the trial
13. Sponsors or investigators directly involved in the trial or their family members
14. The researcher believes that there is any reason not to be accepted